



## Joint Symposium 5

EANM Psychiatry Working Group / European Psychiatric Association (EPA) Neuroimaging Section

**Monday, October 19, 16:45–18:15**

## Session Title

**What Can Nuclear Medicine Offer in Psychiatry?**

## Chairpersons

**Marcella Bellani** (Verona, Italy)

**Francesco Fraioli** (London, United Kingdom)

## Programme

- 16:45–16:50 **Marcella Bellani / Francesco Fraioli** (Verona, Italy / London, United Kingdom): Introduction and Introductory Video Message from Prof. Andrea Fiorillo, President of the EPA
- 16:50–17:15 **Ulrich Müller** (Cambridge/St Helier, United Kingdom/Jersey): PET Psychiatry: The Psychiatrist's Perspective
- 17:15–17:40 **Swen Hesse** (Leipzig, Germany): The Use of Nuclear Medicine Imaging in Biological Research and Clinical Practice of Psychiatric Disorders
- 17:40–18:05 **Fiona Coutts** (Toronto, Canada): Disorders of the Brain: The Future of Neuroimaging for Diagnosing and Treating Psychiatric Disorders in the Age of AI
- 18:05–18:15 All Faculty: Discussion with the Audience

## Educational Objectives

1. Review the historical and current role of SPECT and PET imaging in psychiatric disorders, from biological research to potential clinical applications.
2. Illustrate how nuclear medicine imaging can contribute to understanding disease biology, patient stratification and treatment evaluation in psychiatric conditions, including ADHD, obesity and depressive disorders.
3. Discuss emerging molecular targets, psychopharmacological drug development, multimodal data integration and AI-based approaches at the future interface between psychiatry and molecular imaging.

## Summary

This joint EPA/EANM symposium will examine what nuclear medicine can offer psychiatry across clinical, translational and methodological perspectives. The session will combine a clinical psychiatric viewpoint, a nuclear medicine/molecular imaging perspective and a forward-looking approach focused on multimodal data, AI and patient stratification. SPECT and PET will be discussed not only as research tools, but also as approaches to interrogate the biological substrates of psychiatric disorders, identify new molecular targets, support psychopharmacological drug development and refine clinically meaningful phenotypes. ADHD, obesity and depressive disorders will be used as illustrative examples of psychiatric conditions in which molecular imaging may provide mechanistic insight and help bridge psychiatry, neuroscience and precision medicine.

## Key Words



VIENNA

OCTOBER 17 - 21, 2026

[eanm26.eanm.org](http://eanm26.eanm.org)



Psychiatry; Nuclear Medicine; PET; SPECT; Molecular Imaging; Neuroimaging; ADHD; Obesity; Depression; Psychopharmacology; AI; Multimodal Imaging; Patient Stratification